S-4 Filing

BlueRiver in March stepped down from the NYSE to the NYSE American. The decision to transfer to the NYSE American followed heavy redemptions of the SPAC's Class A common stock.

Evergreen is broadly focused on the technology sector in the ASEAN region, though it has yet to announce a deal. The SPAC raised $100 million in a February 2022 IPO. 

Announced in November, the transaction includes $30 million fully committed common stock PIPE. In addition, Mobix Labs has signed a non-binding term sheet with B. Riley Principal Capital for a $100 million equity line of credit.

The SPAC’s current termination deadline is July 6. The extension proposal, if approved, would move the deadline to July 2024.

The SPAC raised $100 million in an October 2021 IPO to target the biotech industry, but has yet to announce a deal.

The SPAC holds almost $311 million in trust and has until July 26 to complete the transaction, although the company has one more three-month extension it can deploy to get the deal across the finish line. That would require another $1.7 million deposit into trust.

The SPAC raised $150 million in an IPO two years ago to target consumer product, service and media companies at the intersection of sports, entertainment, digital media and/or technology.

The proposed transaction, assuming no redemptions and with PIPE financing of $120 million, is expected to raise approximately $183 million.

Avertix is a medical implant company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks.

Frontier Investment raised $200 million almost two years ago to focus on the technology, digital media, e-commerce, financial technology, or digital services sectors.